Among the signaling pathways altered in GBM, also Cer and S1P, which are known to play an opposite role in the regulation of glioma cell fate promoting cell death and cell survival, respectively, are established to play critical roles in GBM pathophysiology and therapeutics, and therefore, they are currently being studied as promising targets able to increase the effect of the standard treatment [46]. The gene discussed is CBLN1; the disease is glioma.